Novel Calcitonin Gene-Related Peptide (CGRP)-Targeted Therapies for Migraine: A Review of Current Evidence
DOI:
https://doi.org/10.70577/nhdgp184Keywords:
Migraine, CGRP, monoclonal antibodies, gepants, migraine prevention, targeted therapyAbstract
Introduction: Migraine is a highly prevalent neurological disorder and one of the leading causes of disability worldwide. The identification of calcitonin gene-related peptide (CGRP) as a key mediator in its pathophysiology has driven the development of targeted therapies that have demonstrated promising results in the prevention and treatment of this condition.
Objective: To analyze the recent scientific evidence regarding the efficacy and safety of therapies targeting the calcitonin gene-related peptide (CGRP) pathway for the prevention and treatment of migraine.
Methods: A narrative literature review was conducted by searching for studies published between 2021 and 2026 in the PubMed, Google Scholar, and ScienceDirect databases. Systematic reviews, meta-analyses and clinical practice guidelines evaluating the efficacy and safety of therapies targeting the CGRP pathway in adult patients with migraine were included.
Results: The reviewed studies show that therapies targeting the CGRP pathway, including monoclonal antibodies and gepants, have demonstrated efficacy in reducing the frequency and intensity of migraine attacks, improving quality of life, and presenting a favorable safety profile. However, variability in clinical response, cost, and the need for further long-term evidence remain important challenges, promoting the search for more personalized therapeutic strategies.
Conclusion: Targeted therapies against the CGRP pathway represent a significant advance in migraine treatment, demonstrating efficacy, safety, and a more specific therapeutic approach compared with conventional treatments. However, variability in clinical response and access limitations highlight the need for continued research to develop strategies that enable a more personalized treatment approach.
Downloads
References
Al-Hassany, L., Boucherie, D. M., Creeney, H., van Drie, R. W. A., Farham, F., Favaretto, S., Gollion, C., Grangeon, L., Lyons, H., Marschollek, K., Onan, D., Pensato, U., Stanyer, E., Waliszewska-Prosół, M., Wiels, W., Chen, H. Z., Amin, F. M., & European Headache Federation School of Advanced Studies (EHF-SAS). (2023). Future targets for migraine treatment beyond CGRP. The Journal of Headache and Pain, 24(1), 76. https://doi.org/10.1186/s10194-023-01567-4 DOI: https://doi.org/10.1186/s10194-023-01567-4
Calcitonin gene-related peptide (CGRP) is a keymolecule released in acute migraineattacks-Successful translation of basic science toclinical practice. (s/f).
de Mora, F., & Messlinger, K. (2024). Is calcitonin gene-related peptide (CGRP) the missing link in food histamine-induced migraine? A review of functional gut-to-trigeminovascular system connections. Drug Discovery Today, 29(4), 103941. https://doi.org/10.1016/j.drudis.2024.103941 DOI: https://doi.org/10.1016/j.drudis.2024.103941
Edvinsson, L. (2021). CGRP and migraine: from bench to bedside. Revue Neurologique, 177(7), 785–790. https://doi.org/10.1016/j.neurol.2021.06.003 DOI: https://doi.org/10.1016/j.neurol.2021.06.003
Eller, M. T., Frank, F., Kaltseis, K., Karisik, A., Knoflach, M., & Broessner, G. (2024). Novel calcitonin gene-related peptide (CGRP) interfering migraine therapies and stroke-A review. International Journal of Molecular Sciences, 25(21), 11685. https://doi.org/10.3390/ijms252111685 DOI: https://doi.org/10.3390/ijms252111685
Fila, M., Chojnacki, J., Sobczuk, P., Chojnacki, C., & Blasiak, J. (2023). Nutrition and calcitonin gene related peptide (CGRP) in migraine. Nutrients, 15(2), 289. https://doi.org/10.3390/nu15020289 DOI: https://doi.org/10.3390/nu15020289
Garelja, M. L., Walker, C. S., & Hay, D. L. (2022). CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists? British Journal of Pharmacology, 179(3), 454–459. https://doi.org/10.1111/bph.15585 DOI: https://doi.org/10.1111/bph.15585
Guo, S., Jansen-Olesen, I., Olesen, J., & Christensen, S. L. (2023). Role of PACAP in migraine: An alternative to CGRP? Neurobiology of Disease, 176(105946), 105946. https://doi.org/10.1016/j.nbd.2022.105946 DOI: https://doi.org/10.1016/j.nbd.2022.105946
Haghdoost, F., Puledda, F., Garcia-Azorin, D., Huessler, E.-M., Messina, R., & Pozo-Rosich, P. (2023). Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia: An International Journal of Headache, 43(4), 3331024231159366. https://doi.org/10.1177/03331024231159366 DOI: https://doi.org/10.1177/03331024231159366
Kuburas, A., & Russo, A. F. (2023). Shared and independent roles of CGRP and PACAP in migraine pathophysiology. The Journal of Headache and Pain, 24(1), 34. https://doi.org/10.1186/s10194-023-01569-2 DOI: https://doi.org/10.1186/s10194-023-01569-2
Lampl, C., MaassenVanDenBrink, A., Deligianni, C. I., Gil-Gouveia, R., Jassal, T., Sanchez-Del-Rio, M., Reuter, U., Uluduz, D., Versijpt, J., Zeraatkar, D., & Sacco, S. (2023). The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. The Journal of Headache and Pain, 24(1), 56. https://doi.org/10.1186/s10194-023-01594-1 DOI: https://doi.org/10.1186/s10194-023-01594-1
Messina, R., Huessler, E.-M., Puledda, F., Haghdoost, F., Lebedeva, E. R., & Diener, H.-C. (2023). Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia: An International Journal of Headache, 43(3), 3331024231152169. https://doi.org/10.1177/03331024231152169 DOI: https://doi.org/10.1177/03331024231152169
Oliveira, R., Gil-Gouveia, R., & Puledda, F. (2024). CGRP-targeted medication in chronic migraine - systematic review. The Journal of Headache and Pain, 25(1), 51. https://doi.org/10.1186/s10194-024-01753-y DOI: https://doi.org/10.1186/s10194-024-01753-y
Pietra, A. D., Kuburas, A., & Russo, A. F. (2025). PACAP versus CGRP in migraine: From mouse models to clinical translation. Cephalalgia: An International Journal of Headache, 45(9), 3331024251364242. https://doi.org/10.1177/03331024251364242 DOI: https://doi.org/10.1177/03331024251364242
Porreca, F., Navratilova, E., Hirman, J., van den Brink, A. M., Lipton, R. B., & Dodick, D. W. (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia: An International Journal of Headache, 44(3), 3331024241238153. https://doi.org/10.1177/03331024241238153 DOI: https://doi.org/10.1177/03331024241238153
Ramírez-Expósito, M. J., Cueto-Ureña, C., & Martínez-Martos, J. M. (2026). Calcitonin gene-related peptide (CGRP): Biology, signaling, pathophysiological roles, and therapeutic applications. International Journal of Molecular Sciences, 27(11), 4973. https://doi.org/10.3390/ijms27114973 DOI: https://doi.org/10.3390/ijms27114973
Rattanawong, W., Rapoport, A., & Srikiatkhachorn, A. (2024). Medication “underuse” headache. Cephalalgia: An International Journal of Headache, 44(4), 3331024241245658. https://doi.org/10.1177/03331024241245658 DOI: https://doi.org/10.1177/03331024241245658
Russo, A. F., & Hay, D. L. (2023). CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiological Reviews, 103(2), 1565–1644. https://doi.org/10.1152/physrev.00059.2021 DOI: https://doi.org/10.1152/physrev.00059.2021
Russo, A. F., & Kaiser, E. A. (2026). CGRP and migraine: Real-world insights and future therapeutic directions. Annual Review of Medicine, 77(1), 415–432. https://doi.org/10.1146/annurev-med-050224-111631 DOI: https://doi.org/10.1146/annurev-med-050224-111631
Sacco, S., Amin, F. M., Ashina, M., Bendtsen, L., Deligianni, C. I., Gil-Gouveia, R., Katsarava, Z., MaassenVanDenBrink, A., Martelletti, P., Mitsikostas, D.-D., Ornello, R., Reuter, U., Sanchez-Del-Rio, M., Sinclair, A. J., Terwindt, G., Uluduz, D., Versijpt, J., & Lampl, C. (2022). European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. The Journal of Headache and Pain, 23(1), 67. https://doi.org/10.1186/s10194-022-01431-x DOI: https://doi.org/10.1186/s10194-022-01431-x
Santos-Lasaosa, S., Belvís, R., Cuadrado, M. L., Díaz-Insa, S., Gago-Veiga, A., Guerrero-Peral, A. L., Huerta, M., Irimia, P., Láinez, J. M., Latorre, G., Leira, R., Pascual, J., Porta-Etessam, J., Sánchez Del Río, M., Viguera, J., & Pozo-Rosich, P. (2022). CGRP en migraña: de la fisiopatología a la terapéutica. Neurología (English Edition), 37(5), 390–402. https://doi.org/10.1016/j.nrl.2019.03.013 DOI: https://doi.org/10.1016/j.nrl.2019.03.013
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Gabriel Mayner Tresol, Jimmy Fernando Yaguana Torres, Julissa Dayanara Macías Dumes, Harry Markus Carpio Calderón, Vivian Suleika Valarezo Bravo (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
